Publicaciones en colaboración con investigadores/as de Hacettepe University (54)

2024

  1. Clinical nutrition in primary care: ESPEN position paper

    Clinical Nutrition

  2. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

  3. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  4. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

    Intensive Care Medicine, Vol. 50, Núm. 4, pp. 502-515

  5. Nutrition for the older adult – Current concepts. Report from an ESPEN symposium

    Clinical Nutrition, Vol. 43, Núm. 8, pp. 1815-1824

  6. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 572-587

  7. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

  8. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

    Brain, Vol. 147, Núm. 8, pp. 2652-2667

  9. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 9, pp. 2132-2141

2023

  1. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  2. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  3. Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities–focused research

    Alzheimer's and Dementia, Vol. 19, Núm. 12, pp. 5817-5836

  4. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  5. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

  6. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

    Microorganisms, Vol. 10, Núm. 4

  2. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)

    Lung Cancer, Vol. 166, pp. 107-113

  3. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

    Pathogens, Vol. 11, Núm. 10

  4. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis

    Expert Review of Anti-Infective Therapy, Vol. 20, Núm. 11, pp. 1455-1476

2021

  1. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

    Journal of Infection, Vol. 83, Núm. 3, pp. 306-313